Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alemtuzumab in Autoimmune Cytopenias
NCT00472433Phase 2Terminated
- Sponsor
- Phramongkutklao College of Medicine and Hospital
- Start
- Mar 2007
- Primary completion
- May 2009
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of alemtuzumab in immune thrombocytopenia (ITP), autoimmune hemolytic anemia (AIHA), Autoimmune neutropenia (AIN), pure red cell aplasia (PRCA), sponsored by Phramongkutklao College of Medicine and Hospital. Started Mar 2007; status: terminated.
02
Drugs
alemtuzumab
03
Conditions
immune thrombocytopenia (ITP)autoimmune hemolytic anemia (AIHA)Autoimmune neutropenia (AIN)pure red cell aplasia (PRCA)
Beyond the preview
Go deeper on NCT00472433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00472433.